Skip to main content

Antigenicity and immunogenicity of transmitted/founder, consensus, and chronic envelope glycoproteins of human immunodeficiency virus type 1.

Publication ,  Journal Article
Liao, H-X; Tsao, C-Y; Alam, SM; Muldoon, M; Vandergrift, N; Ma, B-J; Lu, X; Sutherland, LL; Scearce, RM; Bowman, C; Parks, R; Chen, H; Gao, F ...
Published in: J Virol
April 2013

Human immunodeficiency virus type 1 (HIV-1) vaccine development requires selection of appropriate envelope (Env) immunogens. Twenty HIV-1 Env glycoproteins were examined for their ability to bind human anti-HIV-1 monoclonal antibodies (MAbs) and then used as immunogens in guinea pigs to identify promising immunogens. These included five Envs derived from chronically infected individuals, each representing one of five common clades and eight consensus Envs based on these five clades, as well as the consensus of the entire HIV-1 M group, and seven transmitted/founder (T/F) Envs from clades B and C. Sera from immunized guinea pigs were tested for neutralizing activity using 36 HIV-1 Env-pseudotyped viruses. All Envs bound to CD4 binding site, membrane-proximal, and V1/V2 MAbs with similar apparent affinities, although the T/F Envs bound with higher affinity to the MAb 17b, a CCR5 coreceptor binding site antibody. However, the various Envs differed in their ability to induce neutralizing antibodies. Consensus Envs elicited the most potent responses, but neutralized only a subset of viruses, including mostly easy-to-neutralize tier 1 and some more-difficult-to-neutralize tier 2 viruses. T/F Envs elicited fewer potent neutralizing antibodies but exhibited greater breadth than chronic or consensus Envs. Finally, chronic Envs elicited the lowest level and most limited breadth of neutralizing antibodies overall. Thus, each group of Env immunogens elicited a different antibody response profile. The complementary benefits of consensus and T/F Env immunogens raise the possibility that vaccines utilizing a combination of consensus and T/F Envs may be able to induce neutralizing responses with greater breadth and potency than single Env immunogens.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Virol

DOI

EISSN

1098-5514

Publication Date

April 2013

Volume

87

Issue

8

Start / End Page

4185 / 4201

Location

United States

Related Subject Headings

  • env Gene Products, Human Immunodeficiency Virus
  • Virology
  • Humans
  • HIV-1
  • HIV Antibodies
  • Guinea Pigs
  • Glycoproteins
  • Cross Reactions
  • Antigens, Viral
  • Antibody Affinity
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Liao, H.-X., Tsao, C.-Y., Alam, S. M., Muldoon, M., Vandergrift, N., Ma, B.-J., … Korber, B. (2013). Antigenicity and immunogenicity of transmitted/founder, consensus, and chronic envelope glycoproteins of human immunodeficiency virus type 1. J Virol, 87(8), 4185–4201. https://doi.org/10.1128/JVI.02297-12
Liao, Hua-Xin, Chun-Yen Tsao, S Munir Alam, Mark Muldoon, Nathan Vandergrift, Ben-Jiang Ma, Xiaozhi Lu, et al. “Antigenicity and immunogenicity of transmitted/founder, consensus, and chronic envelope glycoproteins of human immunodeficiency virus type 1.J Virol 87, no. 8 (April 2013): 4185–4201. https://doi.org/10.1128/JVI.02297-12.
Liao H-X, Tsao C-Y, Alam SM, Muldoon M, Vandergrift N, Ma B-J, et al. Antigenicity and immunogenicity of transmitted/founder, consensus, and chronic envelope glycoproteins of human immunodeficiency virus type 1. J Virol. 2013 Apr;87(8):4185–201.
Liao, Hua-Xin, et al. “Antigenicity and immunogenicity of transmitted/founder, consensus, and chronic envelope glycoproteins of human immunodeficiency virus type 1.J Virol, vol. 87, no. 8, Apr. 2013, pp. 4185–201. Pubmed, doi:10.1128/JVI.02297-12.
Liao H-X, Tsao C-Y, Alam SM, Muldoon M, Vandergrift N, Ma B-J, Lu X, Sutherland LL, Scearce RM, Bowman C, Parks R, Chen H, Blinn JH, Lapedes A, Watson S, Xia S-M, Foulger A, Hahn BH, Shaw GM, Swanstrom R, Montefiori DC, Gao F, Haynes BF, Korber B. Antigenicity and immunogenicity of transmitted/founder, consensus, and chronic envelope glycoproteins of human immunodeficiency virus type 1. J Virol. 2013 Apr;87(8):4185–4201.

Published In

J Virol

DOI

EISSN

1098-5514

Publication Date

April 2013

Volume

87

Issue

8

Start / End Page

4185 / 4201

Location

United States

Related Subject Headings

  • env Gene Products, Human Immunodeficiency Virus
  • Virology
  • Humans
  • HIV-1
  • HIV Antibodies
  • Guinea Pigs
  • Glycoproteins
  • Cross Reactions
  • Antigens, Viral
  • Antibody Affinity